Sanofi US News
WEB5 days ago · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB2 days ago · Sanofi expects Dupixent to achieve more than €13 billion in sales in 2024. For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB4 days ago · Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Press Room - Sanofi US News
WEBSep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy …
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Second positive Phase 3 trial for Dupixent® | Sanofi
WEBNov 27, 2006 · Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease.
Dupixent® - Pivotal Trial Results | Sanofi
WEBMar 23, 2006 · Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial. First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB4 days ago · View comments. (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
Press Room - Sanofi US News
WEBMay 31, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Sanofi/Regeneron’s Dupixent approved by FDA to treat …
WEB49 minutes ago · Approximately 300,000 patients in the US will be eligible for the therapy. Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulator’s decision, which makes Dupixent the first biologic medicines ...